Articles

News

CEPI launches a Call for Proposal for innovative analytical technologies to improve vaccine manufacturing speed and equitable access

Deadline for application: 1 May 2026. An application may be submitted at any time; the review process will involve quarterly reviews throughout the 12-month application period

CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more

Scientists at Denmark’s AdaptVac lead pioneering research to develop an all-in-one vaccine against deadly filoviruses

CEPI and the EU’s Horizon Europe programme are funding the development of a single vaccine to protect against Ebola viruses, Marburg, and other filoviruses

A global consortium led by Danish biotech AdaptVac is developing a vaccine that combines AI-designed immunogens, components that trigger immune response, with AdaptVac’s virus-like particle platform, which mimics real viruses to safely stimulate immunity against multiple deadly filoviruses. Read more

SPEAC's Companion Guide for Single Organ Cutaneous Vasculitis

SPEAC has released a comprehensive Companion Guide for the Brighton Collaboration Case Definition of Single Organ Cutaneous Vasculitis (SOCV)

SPEAC announces the release of a comprehensive Companion Guide for the Brighton Collaboration Case Definition of Single Organ Cutaneous Vasculitis (SOCV). This new resource combines a wealth of tools and guidance to standardize vaccine safety assessments and pharmacovigilance efforts worldwide. Read more

Rift Valley Fever workshop summary

published in Vaccine, Volume 54, 30 April 2025

In June 2024, CEPI convened a workshop in Nairobi, Kenya, to discuss epidemiology and modeling for human RVF vaccine development, bringing together representatives from RVF-endemic countries, global collaborators, and international health organizations. This paper summarizes the workshop discussions and priorities. Read more

CEPI has launched the Research Preparedness Program (RPP)

The RPP will support both advanced-stage clinical development of CEPI’s portfolio vaccines against priority diseases and the 100 Days Mission

The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more

Older News Here |